{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:32:19Z","timestamp":1786739539632,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Complete hydatidiform mole affects women in their reproductive age. About 15-20% develops persistent molar gestational trophoblastic neoplasia (GTN), which is linked with delayed (beyond 56 days) normalization of serum \u03b2HCG after surgical evacuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective of the article is to shorten the duration of normalization time of \u03b2HCG with single-dose methotrexate injection in women with high risk complete hydatidiform mole (CHM) after suction evacuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Total 76 women with CHM were randomized into intervention and control groups. In the intervention arm (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 34) women received single dose 100 mg intramuscular methotrexate injection post evacuation and the control group (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 42) had standard care. Surveillance was done in both groups at two weeks intervals for next six months and duration of normalization of \u03b2HCG level was recorded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Total 94.7% women completed follow-up. Mean of normalization time was significantly lower in the intervention group compared to controls (9.7 weeks versus 14.7 week;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01). Time to event curve showed significantly earlier cumulative normalization time for the intervention group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Single-dose 100 mg methotrexate injection is a low-cost, simple intervention to help one out of three women with CHM with high-risk features to achieve normalization of \u03b2HCG within 56 days. This might be helpful for people in resource-poor countries where adherence to prolonged surveillance is poor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_208_22","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T05:53:22Z","timestamp":1667973202000},"page":"6036-6041","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Effect of single-dose methotrexate injection to prevent neoplastic changes in high risk complete hydatidiform mole: A randomised control trial"],"prefix":"10.4103","volume":"11","author":[{"given":"Jhuma","family":"Biswas","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Calcutta National Medical College and Hospital, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyamal","family":"Dasgupta","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, R. G. Kar Medical College and Hospital, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallika","family":"Datta","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Calcutta National Medical College and Hospital, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mousumi","family":"Datta","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Medical College and Hospital, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santa","family":"Saha","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Regional Institute of Ophthalmology, Medical College and Hospital, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthapratim","family":"Pradhan","sequence":"additional","affiliation":[{"name":"Principal College of Medicine, Sagore Datta Hospital, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"R1-20260527","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ygyno.2008.09.005","article-title":"Current management of gestational trophoblastic diseases","volume":"112","author":"Berkowitz","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R2-20260527","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJMcp0900696","article-title":"Clinical practice","volume":"360","author":"Berkowitz","year":"2009","journal-title":"Molar pregnancy. N Engl J Med"},{"key":"R3-20260527","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ygyno.2019.11.032","article-title":"The impact of previous cesarean section (C\/S) on the risk for post-molar gestational trophoblastic neoplasia (GTN)","volume":"156","author":"Cho","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R4-20260527","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/oxfordjournals.humrep.a136472","article-title":"Mini review:Trophoblastic disease:A retrospective view","volume":"1","author":"Ober","year":"1986","journal-title":"Human Reprod"},{"key":"R5-20260527","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(10)60280-2","article-title":"Gestational trophoblastic disease","volume":"376","author":"Seckl","year":"2010","journal-title":"Lancet"},{"key":"R6-20260527","first-page":"842751","article-title":"Gestational trophoblastic disease:A multimodality imaging approach with impact on diagnosis and management","volume":"2014","author":"Dhanda","year":"2014","journal-title":"Radiol Res Pract"},{"key":"R7-20260527","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/AOG.0000000000003625","article-title":"Considering changes in the recommended human chorionic gonadotropin monitoring after molar evacuation","volume":"135","author":"Horowitz","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R8-20260527","doi-asserted-by":"crossref","first-page":"e2830","DOI":"10.6061\/clinics\/2021\/e2830","article-title":"Impact of clinical characteristics on human chorionic gonadotropin regression after molar pregnancy","volume":"76","author":"Gockley","year":"2021","journal-title":"Clinics (Sao Paulo)"},{"key":"R9-20260527","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.31557\/APJCP.2020.21.6.1755","article-title":"Prophylactic chemotherapy with methotrexate leucovorin in high-risk hydatidiform mole","volume":"21","author":"Aminimoghaddam","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"key":"R10-20260527","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.ajog.2006.03.048","article-title":"Single-dose methotrexate regimen in the treatment of low-risk gestational trophoblastic neoplasia","volume":"195","author":"Chan","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"R13-20260527","first-page":"3381","article-title":"The impact of ultrasonographic lesion size and initial human chorionic gonadotropin values on treatment success in cases with complete hydatidiform mole","volume":"17","author":"Seckin","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R14-20260527","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/AOG.0000000000003566","article-title":"Gestational trophoblastic neoplasia after human chorionic gonadotropin normalization following molar pregnancy:A systematic review and meta-analysis","volume":"135","author":"Albright","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R15-20260527","doi-asserted-by":"crossref","first-page":"401.e1","DOI":"10.1016\/j.ajog.2021.05.006","article-title":"Gestational trophoblastic neoplasia after human chorionic gonadotropin normalization in a retrospective cohort of 7761 patients in France","volume":"225","author":"Descargues","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"R16-20260527","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/01.AOG.0000174583.51617.25","article-title":"Postevacuation \u03b2 HCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy","volume":"106","author":"Wolfberg","year":"2005","journal-title":"Obstet Gynecol"},{"key":"R17-20260527","first-page":"588","article-title":"Outcome of pregnancies occurring within 1 year of hydatidiform mole","volume":"94","author":"Tuncer","year":"1999","journal-title":"Obstet Gynecol"},{"key":"R18-20260527","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/01.AOG.0000136099.21216.45","article-title":"Low risk of relapse after achieving undetectable \u03b2 HCG levels in women with complete molar pregnancy","volume":"104","author":"Wolfberg","year":"2004","journal-title":"Obstet Gynecol"},{"key":"R19-20260527","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.AOG.0000227754.12848.4e","article-title":"Low risk of relapse after achieving undetectable \u03b2 HCG levels in women with partial molar pregnancy","volume":"108","author":"Wolfberg","year":"2006","journal-title":"Obstet Gynecol"},{"key":"R20-20260527","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ygyno.2007.03.010","article-title":"Recurrent gestational trophoblastic disease after \u03b2 HCG normalization following hydatidiform mole in The Netherlands","volume":"106","author":"Kerkmeijer","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R21-20260527","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1471-0528.2007.01320.x","article-title":"Shortened duration of human chorionic gonadotrophin surveillance following complete or partial hydatidiform mole:Evidence for revised protocol of a UK regional trophoblastic disease unit","volume":"114","author":"Sebire","year":"2007","journal-title":"BJOG"},{"key":"R22-20260527","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ygyno.2013.03.010","article-title":"Risk of gestational trophoblastic neoplasia after \u03b2 HCG normalisation according to hydatidiform mole type","volume":"130","author":"Schmitt","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R23-20260527","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ygyno.2015.09.012","article-title":"Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation","volume":"139","author":"Braga","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R24-20260527","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejogrb.2018.02.001","article-title":"Does a human chorionic gonadotropin level of over 20,000\u202fIU\/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?","volume":"223","author":"Braga","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R25-20260527","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ygyno.2017.12.008","article-title":"What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients","volume":"148","author":"Coyle","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R26-20260527","first-page":"243","article-title":"Normal human chorionic gonadotropin regression curves in uneventful postmolarpatients","volume":"57","author":"Kizaki","year":"2012","journal-title":"J Reprod Med"},{"key":"R27-20260527","first-page":"CD007289","article-title":"Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia","volume":"9","author":"Wang","year":"2017","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_208_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:29:48Z","timestamp":1786735788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_208_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_208_22","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"2022-01-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}